Revelation Biosciences REVB
NASDAQ REVB
$1.09 +0.00 (+0.00%)
At close: Aug 21, 2026 · 4:00 PM EDT

Revelation Biosciences (REVB) Cash from Investing Activities (2021 - 2024)

Revelation Biosciences (REVB) posted quarterly Cash from Investing Activities of $17689.0 for Q4 2024, up 200.01% quarter-over-quarter from -$17688.0 in Q3 2024.

Revelation Biosciences (REVB) Cash from Investing Activities (2021 - 2024) Analysis & Trends

Revelation Biosciences (REVB) has reported Cash from Investing Activities for 2 consecutive years, with $17689.0 the latest figure, recorded in Q4 2024.

  • In Q4 2024, Cash from Investing Activities changed N/A year-over-year to $17689.0; the TTM figure through Dec 2024 stood at -$19171.0 (changed N/A YoY), while the FY2024 annual figure was -$19171.0, changed N/A from the prior year.
  • Cash from Investing Activities climbed to $17689.0 in Q4 2024 per REVB's latest filing, from -$17688.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $17689.0 in Q4 2024 and bottomed at -$99101.0 in Q1 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -45.80 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -92.70 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 329.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -49.35 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -363.46 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -3.17 Bn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 24.51 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -229.72 Mn
10 Revelation Biosciences 4.17 Mn -7.33 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 17,689.00
Dec 31, 2024 17,689.00
Sep 30, 2024 -17,688.00
Sep 30, 2024 -17,688.00
Mar 31, 2024 -19,172.00
Mar 31, 2024 -19,172.00
Dec 31, 2021 16,153.00
Dec 31, 2021 16,153.00
Jun 30, 2021 -49,015.00
Jun 30, 2021 -49,015.00
Mar 31, 2021 -99,101.00
Mar 31, 2021 -99,101.00